Concepedia

Publication | Open Access

A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

DOIFull Paper Access

106

Citations

9

References

2010

Year

Alaa Alkhalaf, Astrid Klooster, Willem van Oeveren, U. Achenbach, Nanne Kleefstra, Robbert J. Slingerland, G. Sophie Mijnhout, Henk J.G. Bilo, Rijk O. B. Gans, Gerjan Navis,
Diabetes Care

Abstract

In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.

References

YearCitations

Page 1